Live Breaking News & Updates on நிறுவனம் தி பொதுவானது|Page 4

Stay updated with breaking news from நிறுவனம் தி பொதுவானது. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Intellipharmaceutics Announces Second Quarter 2021 Results


Intellipharmaceutics Announces Second Quarter 2021 Results
ACCESSWIRE
16 Jul 2021, 06:55 GMT+10
TORONTO, ON / ACCESSWIRE / July 15, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ( Intellipharmaceutics or the Company ), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2021. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
Effective May 5, 2021 our exclusive license agreements with Tris Pharma, Inc. for generic Seroquel XR®, generic Pristiq® and generic Effexor XR® were mutually terminated. Products were never supplied nor distributed under the licenses. Termination of the exclusive agreements may provide opportunity for the Company to explore options of supplying the products to multiple sources ....

United States , Purdue Pharma , Isa Odidi , Company Oxycodone , Company Contact , Party Transaction , Company The Common , United States District Court , Risk Management Advisory Committee , Tris Pharma Inc , Drug Products Advisory Committee , Toronto Stock Exchange , Intellipharmaceutics International Inc , Company Aximris , Health Canada , Intellipharmaceutics International , Tris Pharma , Private Placement , Common Shares , Common Share , Common Shares , United States Securities Act , Private Placement , Analgesic Drug Products Advisory Committee , Drug Safety , Advisory Committees ,